UNCONTROLLED COPY FOR PERSONAL USE, THE SIGNED ORIGINAL IS HELD BY THE ICRF QA MANAGER
|
|
- Sybil Lang
- 5 years ago
- Views:
Transcription
1 Title: SOP for Monitoring of Clinical Trials by ICRF Reference Number Author(s): Contact Details: Reviewer(s): ICRF-OR16.02 Jacob Bonner, Quality Assurance and Governance Manager Date written/revised: 03 Jan 2019 Approved by: Name, signature and date Ratified by: Name, signature and date Athanasia Gravani, Quality Officer ICRF Senior Management Team Q,H&S Committee Date SOP becomes Live: 18 February 2019 Due date for revision: 18 February 2022 Target Audience: Location of SOP: Related SOPs and Policies: Refer to section 7 Anyone involved in studies which are monitored by ICRF Electronic: Paper: ICRF Master File, Nurses Station, Staff Lounge This is a controlled document. Users may generate copies for training and reference purposes. Imperial CRF staff and researchers using the facility will be notified as updates become available but they are responsible for replacing local obsolete copies and ensuring staff are appropriately trained. QA Manager Use Only This section to be completed in red ink on controlled copies. All other copies are uncontrolled and the user is responsible for ensuring they use the current version. Controlled copy number Location Signature and date UNCONTROLLED COPY FOR PERSONAL USE, THE SIGNED ORIGINAL IS HELD BY THE ICRF QA MANAGER Document version numbering Version Date Updated by Reason for change 1 April 2018 Alan Sahin New SOP 2 January 2019 Jacob Bonner Changes related to drafting of monitoring plan, tracking visits and oversight of monitoring. ICRF-OR16.02 Clinical Trial Monitoring v2.0, 03JAN2019 Page 1 of 6
2 1.0 Background The NIHR Imperial CRF (ICRF) supports a broad range of clinical research studies involving both patients and healthy volunteers. A fundamental factor in conducting a clinical trial is efficient data collection and management which is then analysed to achieve the stated objectives of the study. Data management processes are required to ensure that the clinical trial report or publication contains results which are accurate and were captured in accordance with the clinical trial protocol. Only data that is relevant for the purpose of the Clinical trial should be recorded. 2.0 Purpose The EU Clinical Trials Directive 2001/20/EC, the GCP directive 2005/28/EC and the Medicines for Human Use Regulations 2004 (SI 2004/1031) set out the requirements for implementation of Good Clinical Practice (GCP) in clinical trials which involve the use of a medicinal product in humans in Europe and the UK. ICH E6 Good Clinical Practice guidance (E6 ICH-GCP; ) defines the purpose of clinical trial monitoring as verification of the following: a) Adequate protection of the rights and well-being of human subjects. b) The investigator is in compliance with applicable regulatory requirements, GCP guidelines, and the clinical study protocol. c) The reported clinical trial data are accurate, complete and verifiable from source documents. According to ICH GCP (5.18.3) the sponsor should determine the extent and nature of monitoring based on an assessment of the study including the objective, complexity, and endpoints of the clinical trial. For Imperial College London (ICL) and Imperial College Healthcare NHS Trust (ICHNT) sponsored trials, these responsibilities are delegated to the Chief Investigator. The purpose of this SOP is to provide detailed instructions for clinical trial monitoring where the ICRF has been given this responsibility and ensuring this is conducted, recorded and reported in accordance with GCP, protocol, SOPs and the applicable regulatory requirements. 3.0 Scope The SOP applies to all studies where the ICRF is responsible for carrying out monitoring activities. Any member of the ICRF core staff may carry out monitoring activities provided they are appropriately qualified and trained, and provided they have been delegated by the sponsor. For studies where the ICRF is not responsible for carrying out monitoring activities, monitoring will be conducted according to the sponsor s policies and procedures and will be facilitated by the ICRF. 4.0 Roles and Responsibilities 4.1 Sponsor Has the overall responsibility for the conduct of its studies, including ensuring the final output i.e. clinical study report or publication- contains results which are accurate and captured in accordance with the clinical trial protocol. In accordance with Good Clinical Practice (GCP) the sponsor should ensure appropriately qualified individuals are responsible for the overall conduct of the trial, handling of the data, verification of the data, conducting the statistical analysis and preparing the trial reports. 4.2 CI/PI The sponsor may delegate the task of ensuring that appropriate data management systems are in place before the study starts. The CI reviews and approves the trial s risk-based monitoring and data management plans on behalf of the sponsor. The PI is responsible for the ICRF-OR16.02 Clinical Trial Monitoring v2.0, 03JAN2019 Page 2 of 6
3 delivery of the study at their site and should work with the monitor to ensure that all findings are addressed. 4.3 Project Manager The Clinical Project Manager (CPM) is responsible for managing the trial on behalf of the sponsor / CI and will help to ensure that the study is appropriately monitored by facilitating on-site visits and helping to ensure that the Corrective and Preventative Actions (CAPAs) are appropriately implemented. The CPM will retain oversight of monitoring where this has been contracted to a 3 rd party. 4.4 Research/site staff (e.g. Doctors, Research Nurses, Clinical Trial Coordinators and Data Managers) They are responsible for collection of the source data, data entry and resolution of monitoring queries. 4.5 Monitor Appointed by the sponsor or their delegate to monitor the trial in accordance with the agreed risk-based monitoring plan. 5.0 Glossary CAPA CI CPM CRF ecrf GCP ICRF MHRA MVR PI SOP SUSAR TMF Corrective and Preventative Action Chief Investigator Clinical Project Manager Case Report Form Electronic Case Report Form Good Clinical practice NIHR Imperial Clinical Research Facility Medicines and Healthcare Products Regulatory Agency Monitoring Visit Report Principal Investigator Standard Operating Procedure Suspected Unexpected Serious Adverse Reaction Trial Master File 6.0 Procedure Clinical trial monitoring serves to provide ongoing oversight of clinical trial activities. The frequency of monitoring visits is based on the risk assessment and the requirements are specified in the clinical trial monitoring plan (ICRF-OR16 Fm1). The monitoring plan will be written by the monitor (or another qualified member of the team delegated by the CI) and approved by the Chief Investigator (CI) and the ICRF Quality Assurance and Governance Manager (QAGM). 6.1 Creating and Maintaining the Risk-based Monitoring Plan The monitoring plan should take into account risks identified in the protocol and the Clinical Risk Assessment and Management Plan (ICRF-OR09 Fm3). It will contain a monitoring-specific risk assessment, upon which the remainder of the plan will be based. It will set out in detail all aspects of the monitoring to be conducted, including the level of central and on-site monitoring, frequency of visits and areas of trial conduct to be reviewed The monitoring plan template (ICRF-OR16 Fm1) will be completed and signed off by the monitor, the CI and the ICRF QAGM prior to enrolment of the first participant in the ICRF. ICRF-OR16.02 Clinical Trial Monitoring v2.0, 03JAN2019 Page 3 of 6
4 6.1.3 The monitoring plan will specify to which participating sites it applies. Monitoring of external sites may be contracted to a 3 rd party, in which case a separate monitoring plan will be required, which will need to be reviewed and approved by the CI prior to the site commencing recruitment. Monitoring documentation generated by 3 rd parties under contract may use different templates Once finalised, the signed monitoring plan will be sent to each participating site to which it applies. Where monitoring has been contracted to a 3 rd party, they will be responsible for providing the monitoring plan to applicable sites, in accordance with their own procedures The monitoring plan will be periodically reviewed and updated whenever required. As a minimum the monitoring plan will be reviewed at the time of each substantial amendment to the trial and following identification of any serious breach of GCP in the trial. Any changes to the monitoring plan will be agreed by the monitor, the CI and the ICRF QAGM. Updated versions of the monitoring plan will be provided to all applicable participating sites. 6.2 Scheduling On-site Monitoring Visits: The trial monitor will schedule on-site visit(s) with the Principal Investigator (PI), the CPM and other relevant staff with at least 10 working days advance notice of the visit date, unless there is a serious issue requiring a more urgent visit. Internal visits confined to the ICRF may also be arranged at shorter notice where agreed by relevant staff The monitor will liaise directly with relevant staff when scheduling visits to departments outside the ICRF, such as pharmacy or radiology unless advised otherwise by the main site contact The monitor will require confirmation that the study files and all required source data will be available for the monitoring visit. At each visit, the monitor will review progress with previously agreed CAPAs The monitor will send written confirmation to the PI and CPM or equivalent, confirming the date and time of the visit, and outline the purpose of the visit Once dates are confirmed, the planned visit will be added to the monitoring tracker which is held on the ICRF shared network drive The following actions will be taken as part of the preparation for each on-site visit: Review of the monitoring plan Identification of the CRFs to be reviewed A preliminary review of the status of the CRF / ecrf should be carried out where possible to check data completeness Review of previous monitoring visit reports (MVRs), follow up letters, correspondence, and outstanding items to resolve ahead of the monitoring visit. Liaison with the site staff to identify any significant issues which have occurred since the previous visit and may require additional time during the planned monitoring visit (e.g. protocol deviations, SUSARs etc) ICRF-OR16.02 Clinical Trial Monitoring v2.0, 03JAN2019 Page 4 of 6
5 Review of recruitment rate in relation to the target/expected rate, in order to document the possible reasons for slow recruitment and plan actions to facilitate the overall study schedule. The reasons should be discussed with the ICRF CPM and a follow up plan be agreed with the site staff 6.3 Monitoring Outcomes Every monitoring activity will be documented in writing. Any observations, findings, CAPAs and responses from on-site visits will be documented using the MVR (template: ICRF-OR16 Fm2) which will be reviewed by the QAGM before sending to the site. The final MVR will be sent to the PI and other relevant staff within 10 working days of the visit. The final signed MVR and all relevant communications will be filed in the ISF, pharmacy file or TMF (as applicable) Central monitoring and other less formalised monitoring activities may be documented via correspondence CAPAs should normally be implemented by the time of the next monitoring visit unless otherwise agreed. The timeframe will be specified for major or critical findings. The monitor will review at least 20% of completed CAPAs to verify that they have been resolved as required and all CAPAs for major or critical findings A copy of the MVR and all relevant communications with participating sites should be stored in the TMF The monitor should discuss any significant findings and proposed CAPAs with the relevant site staff in person wherever possible before issuing the MVR Findings from previous visits which have not been resolved should be checked and will be followed up at subsequent monitoring visits The monitor will maintain a tracker of visits and CAPAs, and will communicate regularly with the QAGM and relevant CPMs to provide monitoring progress updates The monitor will report the following to the ICRF QAGM immediately and where required these issues will be escalated to the sponsor and/or regulatory authorities in accordance with applicable policies and procedures: Potential serious breach of GCP Suspected Fraud or Research Misconduct Persistent failure to implement agreed CAPAs Persistent failure of site staff to attend monitoring visits Obstruction of monitoring activities 6.4 Oversight of Monitoring The PI, CPM, QAGM and sponsor will maintain oversight of monitoring activities Where monitoring has been contracted to a 3 rd party, sponsor oversight will be described in the monitoring plan and may be achieved via one or more of the following means: ICRF-OR16.02 Clinical Trial Monitoring v2.0, 03JAN2019 Page 5 of 6
6 CPM receipt of monitoring reports. Where possible, these will be reviewed for obvious errors and inconsistencies. If required, documentation may be translated into English. Copies of reports will be provided to JRCO upon request. A random sample of data may be selected periodically for central review. The CI, CPM or other ICRF staff may liaise directly with the local site staff via . The sponsor may request further information or conduct audits at any time. 7.0 Related Documents and References: ICRF-OR09 Fm3 Clinical Risk Assessment and Management Plan ICRF-OR16 Fm1 Monitoring Plan Template ICRF-OR16 Fm2 Monitoring Report Template ICRF-OR16 Fm3 Monitoring Visit Checklist ICRF-OR16 Fm4 Monitoring Site Visit Log Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended) ICH Good Clinical Practice (E6): S tep_4_2016_1109.pdf 8.0 Appendices ICRF-OR16.02 Clinical Trial Monitoring v2.0, 03JAN2019 Page 6 of 6
SOP-QA-28 V2. Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Richard Cowie, QA Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head
More informationStandard Operating Procedure (SOP) for Reporting Serious Breaches in Clinical Research
Standard Operating Procedure (SOP) for Reporting Serious Breaches in Clinical Research For Completion by SOP Author Reference Number PHT/RDSOP/002 Version V2.0 07 Apr 2016 Document Author(s) Document Reviewer(s)
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM-005 SOP category: Trial Management Version number: 04 Version date: 10 July
More informationResearch Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004
Title: Outcome Statement: Research Auditing and Monitoring Procedures Researchers in the Trust and research partners will be informed about the requirements and procedures involved in research audit and
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM 005 SOP category: Trial Management Version number: 03 Version date: 19 December
More informationStandard Operating Procedure (SOP)
Standard Operating Procedure MANAGEMENT OF BREACHES IN RESEARCH SETTING AUDIENCE ISSUE Trustwide for research sponsored by UHBristol All research staff involved in UH Bristol sponsored research This SOP
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Risk Assessment SOP-RES-002 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s)
More informationStandard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH. Chief and Principal Investigators of research sponsored and/or hosted by UHBristol
Standard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH SETTING FOR STAFF ISSUE Trustwide Chief and Principal Investigators of research sponsored and/or hosted by UHBristol Oversight of research
More informationStudy Monitoring Plan Template
Study Monitoring Plan Template Sponsor Reference Number: Study Title: Principal Investigator: Study Centre: The Sponsor risk assessment form and the trial risk based monitoring strategy appendices 2 &
More informationSponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law
EU Directives Pharmacovigilance Legislation, SOPs and Reporting Louise Boldy, Governance & Safety Manager David Martin, Pharmacovigilance Monitor EU Legislation 2001/20/EC 2005/28/EC EudraLex Vol 10 UK
More informationMANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS
MANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS DOCUMENT NO.: CR010 v4.0 AUTHOR: Heather Charles ISSUE DATE: 01 September 2016 EFFECTIVE DATE: 15 September 2016 1 INTRODUCTION 1.1 The Academic
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Study Management and Handover SOP-RES-012 Version Number 3 Issue Date 19 th April 2017 Effective Date 2 nd June 2017 Review Date 2 nd June 2019 Author(s)
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Delegated Responsibilities in Research Projects SOP Number: 11 Version Number: 2.0 Supercedes: 1.0 Effective date: August
More informationKeele Clinical Trials Unit
Keele Clinical Trials Unit Standard Operating Procedure (SOP) Summary Box Title SOP Index Number SOP 21 Version 4.0 Approval Date Effective Date Non-Compliance: Deviations and Serious Breaches of GCP and/or
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Corrective and Preventative Action SOP-QMS-008 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s)
More informationStandard Operating Procedure (SOP) for Reporting Urgent Safety Measures in Clinical Research
Standard Operating Procedure (SOP) for Reporting Urgent Safety Measures in Clinical Research For Completion by SOP Author Reference Number PHT/RDSOP/006 Version V1.1 07 Apr 2016 Document Author(s) Document
More informationSOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY. Contact Jess Bisset, Research Operations Manager x20227
SOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY SETTING FOR STAFF QUERIES Trust wide All staff involved in research Contact Jess Bisset, Research Operations Manager x20227 Guidance 1. Introduction In accordance
More informationResearch Staff Training
REFERENCE: VERSION NUMBER: 3.0 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: Research Infrastructure Manager REVIEWED BY: Research & Innovation Group APPROVED BY: Deputy Director of Research CONTROLLER:
More informationDocument Title: GCP Training for Research Staff. Document Number: SOP 005
Document Title: GCP Training for Research Staff Document Number: SOP 005 Version: 2 Ratified by: Version 2, 04/10/2017 Page 1 of 13 Committee Date ratified: 26/10/2017 Name of originator/author: Directorate:
More informationDocument Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026
Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026 Version: 1.1 Ratified by: Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department:
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Urgent Safety Measures SOP-RES-022 Version Number 1 Issue Date 30 th April 2014 Effective Date 28 th May 2014 Review Date 28 th May 2016 Author(s) Reviewer(s)
More informationSTANDARD OPERATING PROCEDURE SOP 715. Principles of Clinical Research Laboratory Practice
STANDARD OPERATING PROCEDURE SOP 715 Principles of Clinical Research Laboratory Practice Version 1.2 Version date 13.11.2015 Effective date 24.04.2017 Number of pages 9 Review date June 2018 Author Role
More informationSTANDARD OPERATING PROCEDURE SOP 325
STANDARD OPERATING PROCEDURE SOP 325 STUDY START UP ACTIVITIES FOR CLINICAL RESEARCH TRIALS Version 1.4 Version date 28.03.2017 Effective date 28.03.2017 Number of pages 7 Review date April 2019 Author
More informationVersion Number: 003. On: September 2017 Review Date: September 2020 Distribution: Essential Reading for: Information for: Page 1 of 13
CONTROLLED DOCUMENT Reporting Research Incidents and Breaches Policy CATEGORY: CLASSIFICATION: PURPOSE Controlled Number: Document Policy Governance To set out the framework and principles for reporting
More informationResearch & Development Quality Manual
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Richard Cowie, QA Manager Version: 3 Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School Document History
More informationDocument Title: File Notes. Document Number: 024
Document Title: File Notes Document Number: 024 Version: 1.2 Ratified by: Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department: Name of responsible individual: Rachel
More informationMarie-Claire Rickard, Governance and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager
Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of or the Trial Protocol SOP Number: 037 Version Number: 5.0 Effective Date: 17/6/16 Review Date: 17/6/18 Author: Reviewer: Reviewer
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Adverse Event Identification, Recording and Reporting in Clinical Trials of Investigational Medicinal SOP-RES-019 Version Number 2 Issue Date 08 th Dec
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Recording and Reporting Deviations, Violations, Potential Serious Breaches, Serious Breaches and Urgent Safety Measures
More informationM. Rickard, Research Governance and GCP Manager R. Fay Research Governance and GCP Manager Elizabeth Clough, Governance Operations Manager
Standard Operating Procedures (SOP) for: Pharmacovigilance and Safety Reporting for Sponsored non-ctimps SOP Number: 26b Version 2.0 Number: Effective Date: 29th November 2015 Review Date: 3 rd December
More informationDocument Title: Investigator Site File. Document Number: 019
Document Title: Investigator Site File Document Number: 019 Version: 1.1 Ratified by: R&D Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationMonitoring Clinical Trials
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number End of Study Report SOP-RES-027 Version Number 2 Issue Date 15 Apr 2016 Effective Date 26 May 2016 Review Date 26 May 2018 Author(s) Reviewer(s) Natalie
More informationSafety Reporting in Clinical Research Policy Final Version 4.0
Safety Reporting in Clinical Research Policy Final Version 4.0 Category: Summary: Equality Assessment undertaken: Impact Policy The Medicines for Human Use (Clinical Trials) Regulations 2004 and subsequent
More informationDocument Number: 006. Version: 1. Date ratified: Name of originator/author: Heidi Saunders, Senior Portfolio Coordinator
including Roles and Responsibilities for the Conduct of Research Studies and Clinical Trials including CTIMPs (Clinical Trials of Investigational Medicinal Products) Document Number: 006 Version: 1 Ratified
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Routine Project Audit SOP Number: 6 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationMHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager
MHRA Findings Dissemination Joint Office Launch Jan. 2012 Presented by: Carolyn Maloney UHL R&D Manager Purpose of presentation To feed back abridged findings from March 2011 MHRA Statutory Systems Inspection
More informationThis Agreement dated DD/MM/YYYY (the Effective Date ) is between
Clinical Trial Delegation of Sponsorship Responsibilities to Chief This Agreement dated DD/MM/YYYY (the Effective Date ) is between Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, NG7
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Safety Reporting in CTIMPs and ATMPs SOP number: TM-003 SOP category: Trial Management Version number: 04 Version date:
More informationKeele Clinical Trials Unit
Keele Clinical Trials Unit Standard Operating Procedure (SOP) Summary Box Title Safety Reporting and Pharmacovigilance SOP Index Number SOP 20 Version 4.0 Approval Date 31-Jan-2017 Effective Date 14-Feb-2017
More informationTrial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs
R&D Department Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Safety Reporting in CTIMPs and ATMPs SOP number: TM 003 SOP category: Trial Management Version number: 03 Version date:
More informationMarie-Claire Rickard, RG and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager
Standard Operating Procedures (SOP) for: Pharmacovigilance processing for the JRMO SOP Number: 26c Version Number: V1 Effective Date: 5/8/16 Review Date: 5/8/17 Author: Reviewer: Reviewer: Authorisation:
More informationStandard Operating Procedure Research Governance
Research and Enterprise Standard Operating Procedure Research Governance Title: Research Governance Audit SOP Reference Number: QUB-ADRE-08 Date prepared 7 August 008 Version Number: Final v -6.0 Revision
More informationDetails: Approval: Distribution & Storage: Pharmacovigilance for Researchers for UoL / LTHT Sponsored CTIMPs. Standard Operating Procedure
Details: Author: Razwan Mahroof - QA Clinical Trials Monitor SOP Pages: 10 Version No. of replaced SOP: 1.0 Effective date of replaced SOP: 04 December 2015 Approval: Version No: of the SOP being approved.
More informationSTANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager
STANDARD OPERATING PROCEDURE SOP 710 Good Clinical Practice AUDIT AND INSPECTION Version 1.3 Version date 27.02.2018 Effective date 3.03.2018 Number of pages 10 Review date February 2020 Author Role Approved
More informationDocument Title: Research Database Application (ReDA) Document Number: 043
Document Title: Research Database Application (ReDA) Document Number: 043 Version: 1.1 Ratified by: Committee Date ratified: 23 February 2017 Name of originator/author: Rachel Fay Directorate: Medical
More informationSOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup
SOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup Authorship Team: Leanne Quinn for Joint SOP Group on Trial Processes (viz Ian Russell, Anne Seagrove, Jemma Hughes, Yvette
More informationDocument Title: Study Data SOP (CRFs and Source Data)
Document Title: Study Data SOP (CRFs and Source Data) Document Number: SOP047 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationACTIONS/PSOP/001 Version 1.0 Page 2 of 6
1. The purpose of the Pharmacy Site File To enable the designated trust pharmacy to fulfil its role and exercise appropriate control over all aspects of study medication handling, an accurately maintained
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Sponsorship SOP-RES-001 Version Number 3 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s) Teresa
More informationDocument Title: Research Database Application (ReDA) Document Number: 043
Document Title: Research Database Application (ReDA) Document Number: 043 Version: 1 Ratified by: Committee Date ratified: 30 September 2014 Name of originator/author: Directorate: Department: Name of
More informationR. Fay, Research Governance & GCP Manager K. Mahiouz, Clinical Trials Facilitator E. Clough, R&D Governance Operations Manager
Standard Operating Procedures (SOP) for: BH/QMUL Sponsorship of CTIMPs, ATMPs and Clinical Trials of non- CE marked Medicinal Devices Process for Researchers SOP Number: 11a Version Number: V1.0 Effective
More informationStandard Operating Procedures
Clinical Monitoring and Site Verification Procedure Overview To define the standard procedures for preparation and documentation of site visits for clinical monitoring and spoke verification for any NETT
More informationDocument Title: Version Control of Study Documents. Document Number: 023
Document Title: Version Control of Study Documents Document Number: 023 Version: 1.1 Ratified by: Committee Date ratified: 03 OCT 2017 Name of originator/author: Directorate: Department: Name of responsible
More informationCorporate. Research Governance Policy. Document Control Summary
Corporate Research Governance Policy Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date:
More informationStandard Operating Procedure. Essential Documents: Setting Up a Trial Master File. SOP effective: 19 February 2016 Review date: 19 February 2018
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-06-003 Essential Documents: Setting Up a Trial Master File SOP effective: 19 February 2016 Review date: 19 February 2018 SOP author signature:
More information1. INTRODUCTION 2. SCOPE 3. PROCESS
1. INTRODUCTION This document describes the procedure for establishing and maintaining records for staff training and complies with the principles of good clinical practice (GCP) for clinical trials of
More informationEuropean Medicines Agency Inspections ANNEX V TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: PHASE I UNITS
European Medicines Agency Inspections London, 23 July 2008 EMEA/INS/GCP/197215/2005 Procedure no.: INS/GCP/3/V ANNEX V TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: PHASE I UNITS GCP
More informationStandard Operating Procedure
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-07-004 Recording, managing and reporting Adverse Events for Clinical Trials of Investigational Medicinal Products and trials of Advanced
More informationSOP18b: Standard Operating Procedure for Preparing for External Audit and Inspection
SOP18b: Standard Operating Procedure for Preparing for External Audit and Inspection Authorship Team: Jemma Hughes, Tina Morgan, for Joint SOP Group on Trial Processes (viz Leanne Quinn, Ian Russell, Anne
More informationSite Closedown Checklist for UoL Sponsored CTIMP Studies
Site Closedown Checklist for UoL Sponsored CTIMP Studies Site Information Site: Study Title: UoL study number: Centre name: Investigator: Date of Visit: Date of Report Date Responses due by: List of site
More informationQuality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D
Quality Assurance in Clinical Research at RM/ICR GCP Compliance Team, Clinical R&D Slide 1 of 13 What is Quality Assurance? The maintenance of a desired level of quality in a service or product, especially
More informationSTANDARD OPERATING PROCEDURE SOP 205
STANDARD OPERATING PROCEDURE SOP 205 Adverse Events: Identifying, Recording and Reporting for CTIMPs Sponsored by the Norfolk and Norwich University Hospital NHS Foundation Trust Version 2.3 Version date
More informationResearch Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review
Effective: 12/04/2013 Reviewed: 12/04/2015 Name of Associated Policy: Palmetto Health Administrative Research Review Definitions Responsible Positions Equipment Needed Procedure Steps, Guidelines, Rules,
More informationJoint R&D Support Office SOP S-2011 UHL
UNIVERSITY OF LEICESTER & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE STANDARD OPERATING PROCEDURES Joint R&D Support Office SOP S-2011 UHL Site Initiation for
More informationStandard Operating Procedures
Standard Operating Procedures 5.7 Site Initiation Version V1.0 Author/s Approved B Fazekas, S Kochovska D Currow Effective date 30/09/2017 Review date 30/09/2019 DO NOT USE THIS SOP IN PRINTED FORM WITHOUT
More informationAuditing of Clinical Trials
Version 1.2 Effective date: 3 September 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.2 3 Sept 2012 Version 1.1 12 May
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Risk Assessment of NCTU Studies SOP number: TM-020 SOP category: Trial Management Version number: 02 Version date: 16
More informationDocument Title: Document Number:
including Document Title: Document Number: Version: 2.0 Ratified by: Committee Date ratified: 25/01/2018 Name of originator/author: Directorate: Department: Name of responsible individual: Rachel Fay Corporate
More informationMEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS Memorandum of understanding between MHRA, COREC and GTAC
MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Memorandum of understanding between MHRA, COREC and GTAC 1. Purpose and scope 1.1 Regulation 27A of the Medicines for Human Use (Clinical Trials)
More informationGovernance %%.4- r2&% Queen s University Belfast. Standard Operating Procedure Research Governance. r2.aoc7. Research and Enterprise
Queen s University Belfast Research and Enterprise Standard Operating Procedure Research Governance Title: Delegation of Responsibilities SOP Reference QUB-ADRE-005 Date prepared 23 June 2008 Number: Version
More informationGuideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol
1 2 31 January 2017 EMA/430909/2016 3 4 5 Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or Draft Adopted by GCP Inspectors Working Group (GCP IWG) 30 January 2017 Adopted
More informationResearch Adverse Event and Safety Reporting Procedures Outcome Statement: Title:
Title: Research Adverse Event and Safety Reporting Procedures Outcome Statement: Research Teams will be able to correctly identify and report Adverse Events and complete Annual Safety Reports for research
More informationDocument Title: Recruiting Process. Document Number: 011
Document Title: Recruiting Process Document Number: 011 Version: 1.0 Ratified by: Committee Date ratified: 24.06.2014 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationThe GCP Perspective on Study Monitoring
The GCP Perspective on Study Monitoring Heidi Judge, CCRP Sr. Clinical Trials Project Manager Clinical Trials Network and Institute Massachusetts General Hospital 1 Overview Monitoring Basics Who, What,
More informationRisk Assessment and Monitoring
Version 1.3 Effective date: 25 May 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.3 25 May 2012 Version 1.2 29 January 2010
More informationChecklist prior to recruiting first patient
Pre-Site selection Site Initiation Visit (SIV) What kind of questions should you ask How you should prepare for this visit Delegation logs Training logs ECRF/CRF Checklist prior to recruiting first patient
More informationInformed Consent SOP Number: 25 Version Number: 6.0 Effective Date: 1 st September 2017 Review Date: 1 st September 2019
Standard Operating Procedures (SOP) for: Informed Consent SOP Number: 25 Version Number: 6.0 Effective Date: 1 st September 2017 Review Date: 1 st September 2019 Author: Reviewer: Reviewer: Authorisation:
More informationReference Number: UHB 253 Version Number: 1 Date of Next Review: 22/01/2018 Previous Trust/LHB Reference Number: SR-RG-015
Reference Number: UHB 253 Version Number: 1 Date of Next Review: 22/01/2018 Previous Trust/LHB Reference Number: SR-RG-015 Safety Reporting in CTIMPs Standard Operating Procedure Introduction and Aim The
More informationResearch Policy. Date of first issue: Version: 1.0 Date of version issue: 5 th January 2012
Research Policy Author: Caroline Mozley Owner: Sue Holden Publisher: Caroline Mozley Date of first issue: Version: 1.0 Date of version issue: 5 th January 2012 Approved by: Executive Board Date approved:
More informationPOLICY ON RESEARCH RELATED ADVERSE EVENT REPORTING
POLICY ON RESEARCH RELATED ADVERSE EVENT REPORTING CLASSIFICATION TRUST POLICY NUMBER APPROVING COMMITTEE R & D Governance Committee RATIFYING COMMITTEE Quality & Risk Committee DATE RATIFIED October 2009
More informationI2S2 TRAINING Good Clinical Practice tips. Deirdre Thom Neonatal Nurse Coordinator
I2S2 TRAINING Good Clinical Practice tips Deirdre Thom Neonatal Nurse Coordinator Content Principal investigator (slides 3-5) Delegation and delegation log (slides 6-7) Informed consent (slides 8-15) Data
More informationStorage and Archiving of Research Documents SOP 6
Storage and Archiving of Research Documents SOP 6 SOP Title Storage and Archiving or Research Documents (Formerly Storage and Archiving Requirements ) SOP No. SOP 6 Author Consulted Departments Lead Manager
More informationBuilding Quality into Clinical Trials. Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies
Building Quality into Clinical Trials Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies Objectives Identify strategies for developing a Quality Management
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationTRAINING REQUIREMENTS FOR RESEARCH STAFF, INCLUDING GOOD CLINICAL PRACTICE (GCP)
Reference Number: UHB 317 Version Number: 1 Date of Next Review: 7th July 2019 Previous Trust/LHB Reference Number: N/A TRAINING REQUIREMENTS FOR RESEARCH STAFF, INCLUDING GOOD CLINICAL PRACTICE (GCP)
More informationDocument Title: Training Records. Document Number: SOP 004
Document Title: Training Records Document Number: SOP 004 Version: 1 Ratified by: RFL Committee Date ratified: 03.06.2014 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationIDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES
IDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES DOCUMENT NO.: CR012 v2.0 AUTHOR: Raymond French ISSUE DATE: 18 September 2017 EFFECTIVE DATE: 02 October
More informationResearch & Development. Case Report Form SOP. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff
Department Title of SOP Research & Development Case Report Form SOP SOP reference no: R&D GCP SOP 03 Authors: Current version number and date: J H Pacynko and J Illingworth Version 2, 01.02.18 Next review
More information4.2. Clinical Trial Monitor (or Monitor): The person responsible for monitoring the data on behalf of the sponsor or contract research organization.
SOP #: MON-101 Page: 1 of 6 1. POLICY STATEMENT: The DF/HCC understands that external sponsors are required to monitor the progress of clinical investigations and ensure appropriate research data collection
More informationQUALITY TIPS FOR CLINICAL SITES. Athena Thomas-Visel. Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES
QUALITY TIPS FOR CLINICAL SITES Athena Thomas-Visel Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES Purpose of presentation: Share best practices seen from 150+ sites visited Spark conversation
More informationSTANDARD OPERATING PROCEDURE SOP 220. Investigation of allegations of Research Fraud and Misconduct. NNUH UEA Joint Research Office
STANDARD OPERATING PROCEDURE SOP 220 Investigation of allegations of Research Fraud and Misconduct Version 1.4 Version date 27.02.2018 Effective date 2.03.2018 Number of pages 8 Review date February 2020
More informationGCP Training for Research Staff. Document Number: 005
GCP Training for Research Staff Document Number: 005 Version: 1 Ratified by: RFL Committee Date ratified: 03.06.2014 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationSite Qualification and Training (SQT) INFORMATION AND GUIDANCE SHEET FOR SITE SIGNATURE AND DELEGATION OF RESPONSIBILITIES LOG
Site Qualification and Training (SQT) INFORMATION AND GUIDANCE SHEET FOR SITE SIGNATURE AND DELEGATION OF RESPONSIBILITIES LOG INFORMATION AND GUIDANCE SHEET FOR THE COMPLETION OF THE SITE SIGNATURE AND
More informationDocumenting the Story of a Clinical Trial: Concept to CAPA. Lori T. Gilmartin Gilmartin Consulting LLC
Documenting the Story of a Clinical Trial: Concept to CAPA Lori T. Gilmartin Gilmartin Consulting LLC The regulations represent the floor while ethical thinking is the sky. Dr. Thomas Moore Boston University
More informationJoint Statement on the Application of Good Clinical Practice to Training for Researchers
Joint Statement on the Application of Good Clinical Practice to Training for Researchers HRA, MHRA, Devolved Administrations for Northern Ireland, Scotland and Wales v1.1 12/10/17 Summary This joint statement
More information